Prediction and prevention of thromboembolic events with enoxaparin in cancer patients with elevated tissue factor-bearing microparticles: a randomized-controlled phase II trial (the Microtec study)
about
Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapyEstimated glomerular filtration rate is an easy predictor of venous thromboembolism in cancer patients undergoing platinum-based chemotherapyPrimary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy.Circulating microparticles in patients with antiphospholipid antibodies: characterization and associations.White blood cell count measured prior to cancer development is associated with future risk of venous thromboembolism--the Tromsø studyPrimary venous thromboembolism prophylaxis in patients with solid tumors: a meta-analysisCirculating membrane-derived microvesicles in redox biology.A novel pathway of cellular activation mediated by antiphospholipid antibody-induced extracellular vesiclesTumor-derived tissue factor-positive microparticles and venous thrombosis in cancer patients.Proteomic analysis of venous thromboembolism: an update.Revisited role of microparticles in arterial and venous thrombosis.Safety biomarkers in preclinical development: translational potential.Extracellular vesicles: emerging targets for cancer therapy.Clinical models and biochemical predictors of VTE in lung cancer.Toward routine detection of extracellular vesicles in clinical samples.Extracellular vesicles, tissue factor, cancer and thrombosis - discussion themes of the ISEV 2014 Educational DayPrevention and Treatment of Venous Thromboembolism in Patients with Cancer: Focus on Drug Therapy.Microparticles as biomarkers of venous thromboembolic events.Mutant IDH1 and thrombosis in gliomas.Key points to optimizing management and research on cancer-associated thrombosis.Tumor oncogene (KRAS) status and risk of venous thrombosis in patients with metastatic colorectal cancer.Extracellular vesicles from blood plasma: determination of their morphology, size, phenotype and concentration.Oral anticoagulation in people with cancer who have no therapeutic or prophylactic indication for anticoagulation.Parenteral anticoagulation in ambulatory patients with cancer.Coagulation and fibrinolysis in gastric cancer.Tissue-factor-bearing microparticles (MPs-TF) in patients with acute ischaemic stroke: the influence of stroke treatment on MPs-TF generation.Thrombosis in cancer patients: etiology, incidence, and management.Fluorescence triggering: A general strategy for enumerating and phenotyping extracellular vesicles by flow cytometry.The intersection of protein disulfide isomerase and cancer associated thrombosis.[Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy].Central retinal artery occlusion, an early sign of crizotinib resistance in an alk positive adenocarcinoma of lung: A rare case report.Generation of Well-Defined Micro/Nanoparticles via Advanced Manufacturing Techniques for Therapeutic Delivery.
P2860
Q24194257-95C2FE40-A2A3-4E47-AD89-D3E6117B3691Q33577831-B65F0874-6DE2-47F4-A6CF-1C1C10796A48Q34546366-508251AF-69BF-462E-A81F-71B759EC64B5Q34749444-21419868-B07B-45E4-9CC2-0422EE66D12EQ34984444-B2C62AB2-8A34-49F1-B968-56D7BA705412Q35594902-813687F0-8692-4310-9C60-B4F5FB48F35BQ35737756-6395BDDD-26E7-47B6-8560-C04F45EA57FAQ36928587-10F0BDDD-1CC8-4868-924A-5D93B4CAC769Q37169096-0086553B-C41B-4C52-AF4B-2702F6D5684BQ38097846-DC1A6A94-F58E-445D-AEAA-A5271BAE5E4DQ38117725-D5BF6983-D6AF-4E26-992B-FAC6F296EAFEQ38148980-E7D9C4DC-095D-4F40-83AE-F4B8CABCBB80Q38202336-1D079BC7-B62D-40F4-84EE-A0AFBAF0F544Q38205701-44E561F1-B2CA-45D4-B950-B1FE4E1B7F85Q38205945-D52948CE-D761-42FE-BEA6-195542DB459EQ38379177-E2C30178-C199-4A2C-A4D5-72ABCD57E518Q38686333-F9AAD23B-82AB-41B7-9CF1-63891D07D6EFQ38874997-563C1CA4-FE96-4827-B6AE-C883F79CFDDFQ39355644-02FF3237-76B2-41E3-99ED-A097E0F1D017Q39358771-E21027E7-BF06-40CE-B711-5E753EE97F99Q41159101-890BA0C5-4915-43CB-A59E-78DA8AAEB69FQ41608957-4BA89926-5181-48E2-BE05-29A2C37E470BQ47235947-906334E6-7133-4839-8AFA-817C917C4C05Q47551857-70765DF7-0617-4EB8-992D-EA352E868542Q47916707-4C644875-292E-4EAC-82AC-129B36E35210Q48465547-D2D3FE11-DF3D-44D8-8A75-29153E0D6A23Q49332638-43DF617F-252F-4FF1-AB55-9548C33E9427Q50991132-81618368-9723-4DDE-83D4-A8F293D76A9DQ52716147-C224C1DB-D433-4C6A-855F-55E986D50FE4Q52836172-32946831-F47A-4805-9B3B-8F15A781180FQ53766125-93C04ACC-EF0C-46DE-A9DB-97E255412A0FQ54994812-E1B34C4C-C117-4334-94BE-628DCD9B939B
P2860
Prediction and prevention of thromboembolic events with enoxaparin in cancer patients with elevated tissue factor-bearing microparticles: a randomized-controlled phase II trial (the Microtec study)
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Prediction and prevention of t ...... II trial (the Microtec study)
@ast
Prediction and prevention of t ...... II trial (the Microtec study)
@en
type
label
Prediction and prevention of t ...... II trial (the Microtec study)
@ast
Prediction and prevention of t ...... II trial (the Microtec study)
@en
prefLabel
Prediction and prevention of t ...... II trial (the Microtec study)
@ast
Prediction and prevention of t ...... II trial (the Microtec study)
@en
P2093
P2860
P356
P1476
Prediction and prevention of t ...... II trial (the Microtec study)
@en
P2093
Andrea Bullock
Bruce Furie
Craig M Kessler
Donna Neuberg
Elizabeth Buchbinder
Federico Campigotto
Heinz-Joseph Lenz
Howard A Liebman
Jonathan Eneman
Kenneth A Bauer
P2860
P304
P356
10.1111/BJH.12163
P407
P577
2012-12-13T00:00:00Z